Surgery Partners SGRY
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Surgery Partners (SGRY) Core Market Data and Business Metrics
Latest Closing Price
$23.54Price-Earnings Ratio
-17.70Total Outstanding Shares
127.61 Million SharesDividend
No dividendSIC Description
Services-general Medical & Surgical Hospitals, NecPrimary Exchange
NASDAQHeadquarters
310 Seven Springs Way, Brentwood, TN, 37027
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,225,078 Shares | 8.31 | 3/14/2025 | 10,179,630 Shares |
| 1,229,508 Shares | 8.12 | 2/28/2025 | 9,978,610 Shares |
| 1,041,437 Shares | 9.84 | 2/14/2025 | 10,251,894 Shares |
| 2,391,982 Shares | 3.95 | 1/31/2025 | 9,453,869 Shares |
| 900,473 Shares | 11.73 | 1/15/2025 | 10,561,159 Shares |
| 984,814 Shares | 11.17 | 12/31/2024 | 11,005,039 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $300.10 Million |
| Net Cash Flow From Investing Activities, Continuing | $-488.50 Million |
| Net Cash Flow From Operating Activities, Continuing | $300.10 Million |
| Net Cash Flow | $73.60 Million |
| Net Cash Flow, Continuing | $73.60 Million |
| Net Cash Flow From Financing Activities, Continuing | $262 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Preferred Stock Dividends And Other Adjustments | $0 |
| Revenues | $3.11 Billion |
| Diluted Earnings Per Share | $-1.33 |
| Benefits Costs and Expenses | $0 |
| Income Tax Expense/Benefit | $134.60 Million |
| Other Operating Expenses | $2.61 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-52.70 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $180.60 Million |
| Comprehensive Income/Loss | $-40.20 Million |
| Comprehensive Income/Loss Attributable To Parent | $-220.80 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity | $3.20 Billion |
| Temporary Equity | $438.80 Million |
| Accounts Payable | $208.70 Million |
| Liabilities | $4.69 Billion |
| Inventory | $88.40 Million |
| Redeemable Noncontrolling Interest | $438.80 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||